Irinotecan
Irinotecan (CAS 97682-44-5), also known as CPT-11, is an anticancer prodrug that acts as an inhibitor of topoisomerase I. Upon enzymatic activation by carboxylesterase (CCE) to its potent metabolite SN-38, it stabilizes the DNA-topoisomerase I cleavable complex, causing DNA damage and apoptosis. In vitro studies show Irinotecan inhibits various colorectal cancer cell lines, including LoVo (IC50 15.8 μM) and HT-29 (IC50 5.17 μM). Additionally, xenograft models, such as COLO 320, demonstrate pronounced tumor growth suppression. Irinotecan is widely utilized in research to investigate DNA damage mechanisms and therapeutic efficacy in colorectal cancer.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 586.68 |
| Cas No. | 97682-44-5 |
| Formula | C33H38N4O6 |
| Solubility | insoluble in H2O; ≥11.4 mg/mL in DMSO; ≥4.9 mg/mL in EtOH |
| Chemical Name | 4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate |
| SDF | Download SDF |
| Canonical SMILES | O=C(OC1)C(O)(CC)C2=C1C(N(CC3=C4N=C5C(C=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C5)=C3CC)C4=C2)=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
HT29, NMG64/84, COLO-357, MIA PaCa-2 and PANC-1 cells |
|
Preparation method |
The solubility of this compound in DMSO is >29.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.1-1000 μg/ml, 30 min |
|
Applications |
Irinotecan displayed concentration- and time-dependent cytotoxic effects in all tested cell lines. In COLO-357, MIA PaCa-2 and PANC-1 cells, irinotecan increased cell number in G0/G1 and decreased cell number in S- and G2-phase. Low concentration of irinotecan increased cell number in G2-phase in HT29 and NMG 64/84. |
| Animal experiment [2]: | |
|
Animal models |
ICR male mice |
|
Dosage form |
Intraperitoneal injection, 100 mg/kg |
|
Application |
The time course of body weight change after Irinotecan (100 mg/kg i.p.) injection showed a significant dosing time-dependent difference (P |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. HOFMANN C, BUTTENSCHOEN K, STRAETER J, et al. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy[J]. Anticancer research, 2005, 25(2A): 795-804. [2]. Ohdo S, Makinosumi T, Ishizaki T, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice[J]. Journal of Pharmacology and Experimental Therapeutics, 1997, 283(3): 1383-1388. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
